PH12021552135A1 - Methods of treating al amyloidosis - Google Patents

Methods of treating al amyloidosis

Info

Publication number
PH12021552135A1
PH12021552135A1 PH1/2021/552135A PH12021552135A PH12021552135A1 PH 12021552135 A1 PH12021552135 A1 PH 12021552135A1 PH 12021552135 A PH12021552135 A PH 12021552135A PH 12021552135 A1 PH12021552135 A1 PH 12021552135A1
Authority
PH
Philippines
Prior art keywords
amyloidosis
methods
treating
patients
treatment
Prior art date
Application number
PH1/2021/552135A
Other languages
English (en)
Inventor
Carol Karp
Gene Kinney
Radhika Tripuraneni
Wagner Zago
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of PH12021552135A1 publication Critical patent/PH12021552135A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/06—Ray-tracing
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T15/00—Three-dimensional [3D] image rendering
    • G06T15/50—Lighting effects
    • G06T15/506—Illumination models
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
PH1/2021/552135A 2019-03-05 2020-03-05 Methods of treating al amyloidosis PH12021552135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814252P 2019-03-05 2019-03-05
US201962942722P 2019-12-02 2019-12-02
PCT/IB2020/000186 WO2020178638A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Publications (1)

Publication Number Publication Date
PH12021552135A1 true PH12021552135A1 (en) 2022-08-31

Family

ID=70476256

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552135A PH12021552135A1 (en) 2019-03-05 2020-03-05 Methods of treating al amyloidosis

Country Status (17)

Country Link
US (3) US11692024B2 (https=)
EP (2) EP3934689B1 (https=)
JP (2) JP7619953B2 (https=)
KR (1) KR20220019656A (https=)
CN (1) CN113811332A (https=)
AU (1) AU2020231081A1 (https=)
BR (1) BR112021017550A2 (https=)
CA (1) CA3132780A1 (https=)
CL (1) CL2021002318A1 (https=)
FR (1) FR3111560B1 (https=)
IL (1) IL286040A (https=)
JO (1) JOP20210245A1 (https=)
MA (1) MA55209A (https=)
MX (1) MX2021010665A (https=)
PH (1) PH12021552135A1 (https=)
SG (1) SG11202109645QA (https=)
WO (1) WO2020178638A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
AU2021339851A1 (en) * 2020-09-14 2023-04-13 Caelum Biosciences, Inc. Method of treating amyloidosis
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法
US20250345418A1 (en) * 2022-01-11 2025-11-13 Prothena Biosciences Limited Methods of treating al amyloidosis
AR132344A1 (es) * 2023-04-10 2025-06-18 Medimmune Llc Optimización de los dominios de unión al antígeno cd3
TW202547553A (zh) * 2024-02-06 2025-12-16 愛爾蘭商普羅希那生物科學有限公司 治療ａｌ類澱粉變性症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
WO2018005967A1 (en) 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
AU2019429147B2 (en) 2019-02-12 2024-11-14 Prothena Biosciences Limited Treatment of AL amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the CD38 cell membrane molecule on antibody-producing and other immune cells
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis
TW202332465A (zh) 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Also Published As

Publication number Publication date
IL286040A (en) 2021-10-31
JOP20210245A1 (ar) 2023-01-30
FR3111560A1 (fr) 2021-12-24
JP2025063135A (ja) 2025-04-15
WO2020178638A1 (en) 2020-09-10
EP3934689B1 (en) 2025-04-23
EP3934689A1 (en) 2022-01-12
US20250188159A1 (en) 2025-06-12
CN113811332A (zh) 2021-12-17
MX2021010665A (es) 2021-12-10
BR112021017550A2 (pt) 2021-11-09
SG11202109645QA (en) 2021-10-28
US11692024B2 (en) 2023-07-04
JP2022522889A (ja) 2022-04-20
MA55209A (fr) 2022-01-12
EP4582446A2 (en) 2025-07-09
CL2021002318A1 (es) 2022-05-06
JP7619953B2 (ja) 2025-01-22
CA3132780A1 (en) 2020-09-10
KR20220019656A (ko) 2022-02-17
US12240894B2 (en) 2025-03-04
EP4582446A3 (en) 2025-08-13
US20200308260A1 (en) 2020-10-01
US20230331831A1 (en) 2023-10-19
AU2020231081A1 (en) 2021-09-30
FR3111560B1 (fr) 2024-03-22

Similar Documents

Publication Publication Date Title
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
JOP20200309A1 (ar) أجسام مضادة لـ il-11
PH12020552229A1 (en) Il-11ra antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
MX2022009366A (es) Compuestos y usos de estos.
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12021551451A1 (en) Combination hbv therapy
MY190411A (en) Improved uricase sequences and methods of treatment
SA522431538B1 (ar) طُرق وتركيبات لعلاج تساقط الشعر
ZA202103975B (en) Methods of treating disease with magl inhibitors
PH12022550130A1 (en) Enzyme inhibitors
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
JOP20220007A1 (ar) طرق للعلاج أو الوقاية من ضمور العضلات النخاعي
MX2020011738A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
CL2024002103A1 (es) Métodos para tratar amiloidosis al
MX2023008835A (es) Métodos de tratamiento de la amiloidosis al.
WO2019179823A8 (en) Lactobacillus fermentum for treating fructose-related diseases
WO2020186111A3 (en) Vista-binding antibodies and uses thereof
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée
MY207627A (en) Methods of treating psoriasis
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.
MX2021012130A (es) Combinaciones de inhibidores de transcripción e inhibidores de punto de control inmuneitario para el tratamiento de enfermedad.
MX2022013885A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.